CTOs on the Move

Egenesis Bio

www.egenesisbio.com

 
eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis has the capability to solve the global organ crisis by providing an alternative to allotransplantation. eGenesis is uniquely positioned to reinvigorate the field of xenotransplantation by addressing both the key virology and immunology hurdles that have impeded its advancement to date and provide commercially-viable products to save and enhance the lives of patients in need.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.egenesisbio.com
  • 101 Cambridgepark Drive Suite 200
    Cambridge, MA USA 02140
  • Phone: 617.941.7500

Executives

Name Title Contact Details
Knut Niss
 Chief Technology Officer Profile

Funding

Egenesis Bio raised $38M on 03/16/2017
Egenesis Bio raised $100M on 11/07/2019
Egenesis Bio raised $125M on 03/02/2021

Similar Companies

Geo Digm Corporation

Geo Digm Corporation is a Chanhassen, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kriya Therapeutics

Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases.

Trevena

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target G protein coupled receptors, or GPCRs. We are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. We have identified four biased ligand drug candidates: TRV130, an FDA-designated Breakthrough Therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; TRV027 was evaluated in a Phase 2b study for the treatment of acute heart failure; TRV734 has completed phase 1 testing for oral treatment of acute and chronic pain; and TRV250 is in preclinical development for the treatment of migraine. In addition, Trevena has an early stage portfolio of drug discovery programs currently in lead optimization.

Epigentek

Epigentek is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

STAT PHARMACEUTICALS

STAT PHARMACEUTICALS is a Santee, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.